NYSE:BDX

Becton, Dickinson and Price Target, Predictions & Analyst Ratings

$261.95
-0.72 (-0.27 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$260.41
$262.93
50-Day Range
$238.54
$262.88
52-Week Range
$219.50
$267.37
Volume2.89 million shs
Average Volume1.36 million shs
Market Capitalization$75.23 billion
P/E Ratio41.12
Dividend Yield1.26%
Beta0.76

Becton, Dickinson and (NYSE:BDX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 9 Analyst Ratings

Analyst Price Target Consensus

$273.63

High PT$297.00
Average PT$273.63
Low PT$250.00
TypeCurrent
9/19/20 to 9/19/21
1 Month Ago
8/20/20 to 8/20/21
3 Months Ago
6/21/20 to 6/21/21
1 Year Ago
9/20/19 to 9/19/20
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$273.63$273.63$276.75$281.93
Price Target Upside4.46% Upside10.43% Upside10.87% Upside9.44% Upside
Get Becton, Dickinson and Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and (NYSE:BDX) vs. Its Competitors

TypeBecton, Dickinson andMedical CompaniesS&P 500
Consensus Rating Score
2.44
2.73
2.56
Consensus RatingHoldBuyBuy
Price Target Upside122.77% Upside8.38% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
546
63.19%
Underperform Votes
318
36.81%
Avg. Outperform Votes
178
67.17%
Avg. Underperform Votes
87
32.83%
Avg. Outperform Votes
829
69.55%
Avg. Underperform Votes
363
30.45%

Becton, Dickinson and (NYSE:BDX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/6/2021SVB Leerink
R. Newitter
Lower Price TargetMarket Perform$260.00 ➝ $250.00+2.85%
8/6/2021JPMorgan Chase & Co.
DowngradeOverweight ➝ Neutral$276.93 ➝ $265.00+9.02%
5/24/2021Barclays
Initiated CoverageEqual Weight$270.00+10.78%
2/5/2021Citigroup
Boost Price TargetNeutral$273.00 ➝ $280.00+9.46%
2/4/2021Piper Sandler
Boost Price TargetPositive ➝ Overweight$275.00 ➝ $280.00+9.90%
1/29/2021Raymond James
Boost Price TargetOutperform$270.00 ➝ $282.00+7.69%
12/15/2020The Goldman Sachs Group
DowngradeConviction-Buy ➝ Buy
12/15/2020Wells Fargo & Company
DowngradeOverweight ➝ Equal Weight$265.00+10.42%
12/15/2020Morgan Stanley
UpgradeEqual Weight ➝ Overweight$262.00 ➝ $297.00+23.75%
8/10/2020UBS Group
Boost Price TargetNeutral$265.00 ➝ $280.00+8.86%
7/2/2020William Blair
B. Weinstein
Reiterated RatingOutperform
5/12/2020KeyCorp
Matthew Mishan
Reiterated RatingHold
5/8/2020Cfra
Lower Price TargetHold$285.00 ➝ $278.00+8.33%
5/8/2020Stifel Nicolaus
Boost Price TargetBuy$265.00 ➝ $280.00+9.10%
2/6/2020Cowen
Josh Jennings
DowngradeOutperform ➝ Market Perform$306.00 ➝ $275.00+9.02%
8/6/2019Piper Jaffray Companies
Lower Price TargetOverweight$267.00 ➝ $266.00+10.83%
5/10/2019BMO Capital Markets
Lower Price TargetMarket Perform$272.00 ➝ $270.00+19.28%
12/6/2018Deutsche Bank Aktiengesellschaft
Initiated CoverageBuy ➝ Buy$280.00+16.07%
(Data available from 9/19/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles











Becton, Dickinson and (NYSE:BDX) Analyst Ratings Frequently Asked Questions

What is Becton, Dickinson and's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Becton, Dickinson and stock is Hold based on the current 5 hold ratings and 4 buy ratings for BDX. The average twelve-month price target for Becton, Dickinson and is $273.63 with a high price target of $297.00 and a low price target of $250.00. Learn more on BDX's analyst rating history

Do Wall Street analysts like Becton, Dickinson and more than its competitors?

Analysts like Becton, Dickinson and stock less than the stock of other Medical companies. The consensus rating for Becton, Dickinson and is Hold while the average consensus rating for medical companies is Buy. Learn more on how BDX compares to other companies

Do MarketBeat users like Becton, Dickinson and more than its competitors?

MarketBeat users like Becton, Dickinson and stock less than the stock of other Medical companies. 63.19% of MarketBeat users gave Becton, Dickinson and an outperform vote while medical companies recieve an average of 67.17% outperform votes by MarketBeat users.

Is Becton, Dickinson and being downgraded by Wall Street analysts?

Over the previous 90 days, Becton, Dickinson and's stock had 1 downgrade by analysts.

Does Becton, Dickinson and's stock price have much upside?

According to analysts, Becton, Dickinson and's stock has a predicted upside of 10.43% based on their 12-month price targets.

What analysts cover Becton, Dickinson and?

Becton, Dickinson and has been rated by JPMorgan Chase & Co., and SVB Leerink in the past 90 days.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.